Lumbar facet injection for the treatment of chronic piriformis myofascial pain syndrome: 52 case studies
نویسندگان
چکیده
BACKGROUND AND AIMS The aim of this study was to demonstrate the effectiveness of lumbar facet joint injection for piriformis myofascial pain syndrome. METHODS Fifty-two patients with chronic myofascial pain in the piriformis muscle each received a lumbar facet injection into the ipsilateral L5-S1 facet joint region, using the multiple insertion technique. Subjective pain intensity, trunk extension range, and lumbar facet signs were measured before, immediately after, and 2 weeks after injection. Thirty-six patients received follow-up for 6 months. RESULTS Immediately after the injection, 27 patients (51.9%) had complete pain subsidence, 19 patients (36.5%) had pain reduction to a tolerable level, and only 6 patients (11.5%) had no pain relief to a tolerable level. Mean pain intensity was reduced from 7.4±0.9 to 1.6±2.1 after injection (P<0.01). This effectiveness lasted for 2 weeks in 49 patients (94.2%), and lasted for approximately 6 months in 35 (97.2%) of 36 patients. The mean range of motion increased from 13.4±6.8 degrees to 22.1±6.0 degrees immediately after injection, and further increased 2 weeks and 6 months later. Immediately after injection, 45 patients (86.5%) had no facet sign. In addition, 90.4% and 94.4% of patients had no facet sign after 2 weeks and after 6 months, respectively. CONCLUSIONS It is important to identify the possible cause of piriformis myofascial pain syndrome. If this pain is related to lumbar facet lesions, lumbar facet joint injection can immediately suppress piriformis myofascial pain symptoms. This effectiveness may last for at least 6 months in most patients. This study further supports the importance of eliminating the underlying etiological lesion for complete and effective relief of myofascial pain syndrome.
منابع مشابه
Treatment of Piriformis Myofascial Pain Syndrome related to Lumbar Facet Lesion: A Case Report
This case report describes a patient with chronic pain due to piriformis myofascial pain syndrome related to lumbar facet joint lesion. The purpose is to demonstrate the elimination of the underlying etiological lesion by lumbar facet joint injection with steroid suspension for a complete and effective treatment of piriformis myofascial pain syndrome in order to obtain a permanent pain relief. ...
متن کاملEvaluating the Prevalence of Lumbar Myofascial Pain Syndrome in Patients with Non-specific Chronic Low Back Pain and a Normal MRI Study
Abstract Introduction: Low back pain is a very common disorder that affects a significant percentage of people in the community (1). As a non-mechanical cause, myofascial pain is a primary disorder which may produce lumbar and lower limb pain and is not necessarily secondary to other diagnosis (2-5). Trigger points are the main symptoms of myofascial pain which may mimic the radicular pain in ...
متن کاملPiriformis Syndrome in Fibromyalgia: Clinical Diagnosis and Successful Treatment
Piriformis syndrome is an underdiagnosed extraspinal association of sciatica. Patients usually complain of deep seated gluteal pain. In severe cases the clinical features of piriformis syndrome are primarily due to spasm of the piriformis muscle and irritation of the underlying sciatic nerve but this mysterious clinical scenario is also described in lumbar spinal canal stenosis, leg length disc...
متن کاملA comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.
Myofascial pain syndrome (MPS) is a common illness, characterised by acute or chronic focal pain, muscle stiffness and fatigue. The pathophysiology of MPS remains unclear. Previous preliminary studies have demonstrated therapeutic efficacy of the muscle relaxant botulinum toxin type A (BTX-A) in the treatment of MPS. A single-centre, randomised trial compared the effects of BTX-A with the stero...
متن کاملBotulinum Toxin for the Treatment of Myofascial Pain Syndromes Involving the Neck and Back: A Review from a Clinical Perspective
Introduction. Botulinum toxin inhibits acetylcholine (ACh) release and probably blocks some nociceptive neurotransmitters. It has been suggested that the development of myofascial trigger points (MTrP) is related to an excess release of ACh to increase the number of sensitized nociceptors. Although the use of botulinum toxin to treat myofascial pain syndrome (MPS) has been investigated in many ...
متن کامل